0000908662-15-000296.txt : 20150819
0000908662-15-000296.hdr.sgml : 20150819
20150819161451
ACCESSION NUMBER: 0000908662-15-000296
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150817
FILED AS OF DATE: 20150819
DATE AS OF CHANGE: 20150819
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: DYAX CORP
CENTRAL INDEX KEY: 0000907562
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 043053198
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 55 NETWORK DRIVE
CITY: BURLINGTON
STATE: MA
ZIP: 01803-2756
BUSINESS PHONE: 617-250-5769
MAIL ADDRESS:
STREET 1: 55 NETWORK DRIVE
CITY: BURLINGTON
STATE: MA
ZIP: 01803-2756
FORMER COMPANY:
FORMER CONFORMED NAME: BIOTAGE INC
DATE OF NAME CHANGE: 19951117
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MIGAUSKY GEORGE V
CENTRAL INDEX KEY: 0001134365
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-24537
FILM NUMBER: 151064227
MAIL ADDRESS:
STREET 1: C/O DYAX CORP.
STREET 2: 300 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2015-08-17
0000907562
DYAX CORP
DYAX
0001134365
MIGAUSKY GEORGE V
C/O DYAX CORP.
55 NETWORK DRIVE
BURLINGTON
MA
01803-2756
0
1
0
0
EVP & Chief Financial Officer
Common Stock
2015-08-17
4
M
0
65000
3.22
A
136350
D
Common Stock
2015-08-17
4
M
0
51000
10.20
A
187350
D
Common Stock
2015-08-17
4
S
0
64291
22.596
D
123059
D
Common Stock
2015-08-17
4
S
0
51709
23.1653
D
71350
D
Common Stock
2015-08-17
4
S
0
2306
22.7012
D
21694
I
By Trust
Common Stock
2015-08-17
4
S
0
694
23.251
D
21000
I
By Trust
Common Stock
2015-08-17
4
S
0
2436
22.7476
D
18564
I
By Trust
Common Stock
2015-08-17
4
S
0
564
23.2661
D
18000
I
By Trust
Common Stock
2015-08-17
4
S
0
2815
22.8207
D
15185
I
By Trust
Common Stock
2015-08-17
4
S
0
185
23.3781
D
15000
I
By Trust
Stock Option (right to buy)
3.22
2015-08-17
4
M
0
65000
0
D
2020-02-10
Common Stock
65000
125000
D
Stock Option (right to buy)
10.20
2015-08-17
4
M
0
51000
0
D
2024-02-27
Common Stock
51000
93000
D
The sales reported in this Form 4 were effected pursuant to a rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.99, inclusive. The reporting person undertakes to provide to Dyax Corp., any security holder of Dyax Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.46, inclusive. The reporting person undertakes to provide to Dyax Corp., any security holder of Dyax Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 3.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.15 to $23.10, inclusive. The reporting person undertakes to provide to Dyax Corp., any security holder of Dyax Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4.
Shares are held in trusts, of which Mr. Migausky is the trustee, for the benefit of each of Mr. Migausky's children. Mr. Migausky disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $23.15 to $23.47, inclusive. The reporting person undertakes to provide to Dyax Corp., any security holder of Dyax Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 6.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.16 to $23.15, inclusive. The reporting person undertakes to provide to Dyax Corp., any security holder of Dyax Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 7.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $23.17 to $23.47, inclusive. The reporting person undertakes to provide to Dyax Corp., any security holder of Dyax Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 8.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.29 to $23.27, inclusive. The reporting person undertakes to provide to Dyax Corp., any security holder of Dyax Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 9.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $23.30 to $23.47, inclusive. The reporting person undertakes to provide to Dyax Corp., any security holder of Dyax Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 10.
The options became fully exercisable on February 10, 2014.
The options become exercisable in 48 substantially equal installments at the end of each monthly anniversary of the date of grant, February 27, 2014.
/s/ Andrew D. Ashe as attorney-in-fact
2015-08-19